|
|
|
| Clinical Efficacy of Argatroban Sequential Therapy Combined with rt-PA Thrombolysis in the Treatment of Acute Ischemic Stroke |
| XU Xiaoge, LI Jingxue, WEI Mengli |
| Zhengzhou Central Hospital Affiliated to Zhengzhou University,Zhengzhou Henan 450000 |
|
|
|
|
Abstract 【Objective】To investigate the clinical efficacy of argatroban sequential therapy combined with alteplase(rt-PA) thrombolysis in the treatment of acute ischemic stroke(AIS). 【Methods】The clinical data of 96 patients with AIS treated in our hospital from May 2020 to December 2022 were retrospectively analyzed. According to the different treatment schemes, they were divided into observation group and control group, with 48 cases in each group. The control group was given rt-PA thrombolysis, while the observation group was given argatroban sequential therapy on the basis of thrombolysis. The efficacy, neurological injury factors [S100β protein, neuron specific enolase(NSE)], vascular endothelial injury indicators [serum calcitonin gene-related peptide(CGRP), endothelin-1(ET-1)], National Institutes of Health Stroke Scale(NIHSS), modified Rankin Scale(mRS), Barthel Index(BI) score and the incidence of complications were compared between the two groups. 【Results】 After 3 months of treatment, the total effective rate of the study group was higher than that of the control group(P<0.05); After 14 days and 3 months of treatment, S100β and NSE in the observation group were lower than those in the control group(P<0.05); After 14 days and 3 months of treatment, CGRP in the observation group was higher than that in the control group, and ET-1 was lower than that in the control group(P<0.05); After 3 months of treatment, the NIHSS and mRS scores of the observation group were lower than those of the control group, and the BI score of the observation group was higher than that of the control group(P<0.05); There was no significant difference in the total incidence of complications between the two groups(P>0.05). 【Conclusion】The effect of argatroban sequential therapy combined with alteplase in the treatment of AIS is significant, which can reduce vascular endothelial injury, improve neurological function and improve living ability.
|
|
Received: 08 August 2023
|
|
|
|
|
|
[1] 覃奇雄,梁志坚.急性缺血性脑卒中患者静脉溶栓后血压变异性与预后相关性的研究进展[J].中国全科医学,2021,24(3):376-380.
[2] 刘晓文,高永超,王少婵,等.双抗联合纤溶酶治疗急性缺血性脑卒中的量效学研究及预后危险因素分析[J].中华老年心脑血管病杂志,2022,24(6):618-621.
[3] 黄鸿,徐宏伟,俞金娜,等.阿替普酶溶栓治疗急性缺血性脑卒中并发腹膜后出血继发自发性脾破裂一例[J].中华老年心脑血管病杂志,2022,24(4):434-435.
[4] 陈玉萍,陶晓勇,许胜杰,等.阿加曲班抗凝治疗后循环穿支动脉急性脑梗死疗效及安全性评价[J].中华老年心脑血管病杂志,2022,24(6):611-613.
[5] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组.中国缺血性卒中和短暂性脑缺血发作二级预防指南2022[J].中华神经科杂志,2022,55(10):1071-1110.
[6] 李宏建.通过在紧急医疗服务中引入美国国立卫生研究院卒中量表提高急性卒中治疗效率[J].国际脑血管病杂志,2022,30(9):677.
[7] 鲍利改,董谦.丁苯酞辅助瑞替普酶溶栓治疗急性脑梗死的效果及对细胞凋亡因子、mRS评分的影响[J].解放军医药杂志,2022,34(3):90-95.
[8] 李谷维.康复护理对急性脑梗死患者早期预后的影响[J].神经损伤与功能重建,2021,16(6):357-358.
[9] 魏淑琦,孟心怡,阎文静,等.急性轻型缺血性脑卒中患者扩大的血管周围间隙与脑卒中后认知功能障碍的相关性[J].中华神经医学杂志,2022,21(1):20-27.
[10] 颜云,叶民,徐家立,等.阿加曲班联合阿替普酶静脉溶栓治疗对急性脑梗死红细胞聚集指数、神经功能及脑血管储备功能的影响[J].实用医院临床杂志,2022,19(4):114-117.
[11] 王若兰,韩祖成,袁捷,等.阿加曲班联合阿替普酶静脉溶栓治疗急性缺血性脑卒中有效性及安全性的meta分析[J].中国医药导报,2022,19(20):70-74.
[12] 李易蒸,张庆欣,杨晓莉,等.急性缺血性脑卒中侧支循环与血管内皮细胞生长因子和碱性成纤维细胞生长因子的相关性[J].中华老年心脑血管病杂志,2022,24(1):67-70.
[13] 王晓毅,黄海林,成刚.血清Lp(a)、MBP、CGRP在预测脑出血术后早期颅内感染的效能研究[J].临床神经外科杂志,2022,19(5):574-578.
[14] 束梅燕,凌芸,杨淑娴,等.血清S100钙结合蛋白B水平对急性脑出血诊断及预后预测的价值[J].山东医药,2022,62(31):84-86.
[15] 刘霞,陶彦春,王娜,等.神经介入溶栓术治疗急性脑梗死的临床疗效及对患者血清NSE、S-100β及神经生长因子的影响[J].海南医学,2021,32(11):1384-1387. |
|
|
|
2024, Vol. 41 
